Variable | All patients (N = 822) | Alive (N = 712) | Dead (N = 110) | P |
---|---|---|---|---|
Age (yrs) | 77 ± 11 | 77 ± 11 | 80 ± 9 | 0.020 |
≤65 | 129 (16%) | 119 (17%) | 10 (9%) | 0.033 |
66 to 75 | 144 (17%) | 131 (18%) | 13 (12%) | |
76 to 85 | 368 (45%) | 310 (44%) | 58 (53%) | |
>85 | 181 (22%) | 152 (21%) | 29 (26%) | |
Men | 468 (57%) | 408 (57%) | 60 (55%) | 0.587 |
Women | 354 (43%) | 304 (43%) | 50 (45%) | |
Type of VKA treatment | ||||
Fluindione | 631 (77%) | 535 (75%) | 96 (87%) | 0.005 |
Acenocoumarol | 99 (12%) | 91 (13%) | 8 (7%) | 0.098 |
Warfarin | 85 (10%) | 80 (11%) | 5 (5%) | 0.032 |
Missing data | 7 | 6 | 1 | |
Indication for VKA treatment* | ||||
Atrial fibrillation | 555 (68%) | 470 (66%) | 85 (78%) | 0.013 |
Venous thromboembolic disease | 156 (19%) | 143 (20%) | 13 (12%) | 0.043 |
Prosthetic heart valve | 102 (12%) | 89 (13%) | 13 (12%) | 0.850 |
Others | 79 (10%) | 66 (9%) | 13 (12%) | 0.386 |
Duration of VKA treatment | ||||
<1 year | 137 (17%) | 124 (18%) | 13 (13%) | 0.223 |
1 to 5 years | 236 (30%) | 207 (30%) | 29 (29%) | 0.846 |
>5 years | 426 (53%) | 367 (52%) | 59 (58%) | 0.272 |
Missing data | 23 | 14 | 9 | |
Antiplatelet treatment** | 153 (19%) | 132 (19%) | 21 (19%) | 0.895 |
Aspirin | 125 (15%) | 107 (15%) | 18 (16%) | 0.688 |
Clopidogrel | 34 (4%) | 31 (4%) | 3 (3%) | 0.694 |
Missing data | 1 | 1 | 0 | |
History of severe hemorrhage** | 103 (13%) | 93 (13%) | 10 (10%) | 0.331 |
Missing data | 10 | 3 | 7 | |
Type of hemorrhage | ||||
Intracranial | 262 (32%) | 176 (25%) | 86 (78%) | <0.001 |
Gastrointestinal | 264 (32%) | 253 (36%) | 11 (10%) | <0.001 |
Deep-muscle hematomas | 107 (13%) | 103 (15%) | 4 (4%) | <0.001 |
“Other”*** | 189 (23%) | 180 (25%) | 9 (8%) | <0.001 |
Missing data | 0 | 0 | 0 | |
SAP (mmHg) | 135 ± 36 | 131 ± 33 | 154 ± 47 | <0.001 |
SAP | ||||
Hypertension >140 mmHg | 334 (41%) | 263 (37%) | 71 (66%) | <0.001 |
Normotension 90 to 140 mmHg | 411 (50%) | 386 (54%) | 25 (23%) | <0.001 |
Hypotension <90 mmHg | 74 (9%) | 62 (9%) | 12 (11%) | <0.001 |
Missing data | 3 | 1 | 2 | |
GCS | 15 [15] | 15 [15] | 9 [4-15] | <0.001 |
GCS | ||||
>13 | 684 (84%) | 648 (92%) | 36 (33%) | <0.001 |
9 to 13 | 65 (8%) | 45 (6%) | 20 (19%) | <0.001 |
≤8 | 64 (8%) | 12 (2%) | 52 (48%) | <0.001 |
Missing data | 9 | 7 | 2 | |
Admission INR | 4.7 ± 3.4 | 4.7 ± 3.5 | 4.4 ± 2.7 | 0.236 |
Normal (≤1.5) | 45 (5%) | 40 (6%) | 5 (5%) | 0.385 |
Therapeutic (>1.5 to 4) | 394 (48%) | 341 (48%) | 53 (48%) | |
Supratherapeutic (>4) | 345 (42%) | 300 (42%) | 45 (41%) | |
Missing value | 38 (5%) | 31 (4%) | 7 (6%) | |
VKA reversal treatment | ||||
No guideline-concordant | ||||
Level 0 | 361 (44%) | 299 (42%) | 62 (56%) | 0.06 |
Level 1 | 103 (13%) | 92 (13%) | 11 (10%) | |
Level 2 | 34 (4%) | 32 (5%) | 2 (2%) | |
Guideline-concordant | ||||
Level 3 | 90 (11%) | 85 (12%) | 5 (5%) | |
Level 4 | 217 (26%) | 190 (27%) | 27 (25%) | |
VKA reversal treatment | ||||
Not guideline-concordant (Levels 0 + 1 + 2) | 509 (62%) | 432 (61%) | 77 (70%) | 0.06 |
Guideline-concordant (Levels 3 + 4) | 313 (38%) | 280 (39%) | 33 (30%) |